Navigation Links
New study identifies novel role for PEA-15 protein in cancer growth
Date:11/21/2011

HONOLULUA new study from the University of Hawaii Cancer Center reveals that PEA-15, a protein previously shown to slow ovarian tumor growth and metastasis, can alternatively enhance tumor formation in kidney cells carrying a mutation in a cancer-promoting gene called H-Ras.

The H-Ras oncogene is mutated in many human malignancies, and previous reports have shown the ability of H-Ras to contribute to the development, proliferation and metastasis of these tumors. Conversely, PEA-15 had been reported to inhibit tumor cell proliferation and metastasis by opposing H-Ras signals. In ovarian and breast cancer, PEA-15 is proposed to have promising therapeutic potential and in ovarian cancer PEA-15 has shown promise as a marker of prolonged patient survival.

This new study is the first finding of a pro-cancer effect of PEA-15 on proliferation and as such suggests caution in pursuing the use of PEA-15 as an anti-cancer therapeutic. The study results were published online today in the journal Oncogene.

"Our findings reveal a surprising mechanism by which PEA-15 can enhance H-Ras driven transformation of cells, rather than stop it," said Joe W. Ramos, Ph.D., associate professor at the University of Hawaii Cancer Center and co-director of its Cancer Biology Program. "We showed that in a common scenario in which a cell contains a Ras mutation, PEA-15 can accelerate the rate of tumor formation both in vitro and in vivo," he added.

In contrast to reports suggesting a tumor-suppressor function of PEA-15, Ramos said the discovery confirms that PEA 15 expression can also trigger tumor growth. "What we now know is that PEA-15 can either enhance or impair the formation of tumors depending on the signaling pathways active in a specific tumor cell."

"As with most cancers, an interplay of factors determines the fate of a patient," noted Florian Sulzmaier, a researcher at the UH Cancer Center and first author of the newly published study. "PEA-15 might still be worth considering for treatment of certain cancers. However, care should be taken in tumor types that carry Ras mutations that could change the outcome of a therapy."


'/>"/>

Contact: Kellie Tormey
ktormey@cc.hawaii.edu
808-564-5814
University of Hawaii Cancer Center
Source:Eurekalert

Related biology news :

1. UT Dallas research widens study of brains role in tinnitus
2. Study of flower petals shows evolution at the cellular level
3. Study explains how heart attack can lead to heart rupture
4. Study details links between climate, groundwater availability - will help states prepare for drought
5. Long-term study shows acid pollution in rain decreased with emissions
6. New study links excessive amounts of vitamin D to onset of atrial fibrillation
7. Study IDs new genetic links to impulsivity, alcohol problems in men
8. Forests cooler or warmer than open areas depending on latitude, study finds
9. Harm not those strangers that pollinate, study warns
10. MSU researcher sent to Siberia to study global change
11. Trees adapt to poor levels of sunlight to effectively process carbon, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
(Date:11/17/2016)... INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has just ... servers in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016  Renova™ Therapeutics, a biotechnology company ... and type 2 diabetes, announced that it has ... virus (AAV) vector developed in the laboratory of ... Stanford University. The company plans to use this ... product pipeline. "Early research has ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, a leading producer ... using USB or PCI Express, announced the FOMD-ACV-A4, the company's first FPGA-on-Module for ... thin, SODIMM-style module that fits a standard 204-pin SODIMM socket for low-cost integrations ...
(Date:12/8/2016)... Dec. 8, 2016  Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...
(Date:12/8/2016)... ... 08, 2016 , ... Microbial genomics leader, uBiome, joins Google, ... of just six company finalists in the Health & Medicine category. Over 1,000 ... as finalists in this year’s awards include Google, SpaceX, Oculus, and SolarCity. Individuals ...
Breaking Biology Technology: